- Sep 6, 2018

Novartis receives Health Canada approval of its CAR-T cell therapy, Kymriah™

Novartis is pleased to announce that following a Priority Review, Health Canada has approved Kymriah™ (tisagenlecleucel/ CTL019) the first chimeric antigen receptor T cell (CAR-T) therapy to receive regulatory approval in Canada.

Study shows potential of new treatment strategies for most common childhood cancer

Promising target for CAR T cells helps cancer trick the immune system

Palliative Care Important for Young Patients During ‘Identity Development’

Scientists discover new Achilles heel of leukemia cells

Promising investigational therapy improves survival in aggressive childhood brain tumor

Childhood cancer mortality has fallen significantly in the US, but disparities have emerged

St. Jude scientists identify T-cell differentiation nodes to improve cancer-killing

Analysis shows high rate of ‘significant’ health problems in childhood cancer survivors

Fusion oncoprotein forces cell fates toward rhabdomyosarcoma

“DNA loops” in pediatric brain tumors double relapse risk

Recent Posts

Novartis receives Health Canada approval of its CAR-T cell therapy, Kymriah™

Archive

Search By Tags